<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the approach to metastatic breast cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the approach to metastatic breast cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the approach to metastatic breast cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Priyanka Sharma, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harold J Burstein, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although metastatic breast cancer (MBC) is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [
         <a href="#rid1">
          1-3
         </a>
         ]. Median overall survival among patients with metastatic breast cancer now is slightly over three years, with a range from a few months to many years [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with MBC receive systemic medical therapy consisting of chemotherapy, endocrine therapy, targeted therapy and/or biologic therapies, and supportive care measures [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         General principles of management of MBC are presented here. Details of single-agent and combination chemotherapy, endocrine therapy, biologic therapy, and how to select among them, as well as locoregional approaches, osteoclast inhibitors (bisphosphonates and receptor activator of nuclear factor kappa-B [RANK] ligand inhibitors), and supportive care are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/760.html" rel="external">
          "The role of local therapies in metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/761.html" rel="external">
          "Treatment of metastatic breast cancer in older women"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H130595">
         <span class="h1">
          THERAPEUTIC GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary goals of systemic treatment for MBC are prolongation of survival, alleviation of symptoms, and maintenance or improvement in quality of life, while balancing the toxicity associated with treatment [
         <a href="#rid7">
          7-9
         </a>
         ]. The median survival for MBC varies widely based on subtype of tumor, sites of metastatic involvement, and burden of metastatic disease, and some patients experience long-term survival [
         <a href="#rid1">
          1-3,10,11
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H134297">
         <span class="h1">
          TUMOR ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunohistochemical (IHC) subtype based on hormone receptor status and human epidermal growth factor receptor 2 (HER2) overexpression, and tumor burden have both prognostic and predictive value and are important factors in selecting appropriate treatment.
        </p>
        <p>
         Complete evaluation for the extent of metastatic disease includes the following.
        </p>
        <p class="headingAnchor" id="H1918203041">
         <span class="h2">
          Biopsy of metastatic lesion
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advise patients with newly diagnosed, metastatic disease to undergo a repeat biopsy, which will not only establish the diagnosis of MBC, but will also allow a re-examination of receptor status. Results of the metastatic biopsy may make targeted therapies available for those whose initial biopsy did not display hormone receptor or HER2 positivity.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy of metastatic lesion
         </strong>
         – Confirmatory biopsy of a suspected metastatic lesion, with reassessment of estrogen receptor (ER), progesterone receptor (PR), and HER2 overexpression. This is important since change in hormone receptor and HER2 statuses from primary to metastatic disease from positive to negative or negative to positive may impact choice of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         According to American Society of Clinical Oncology/College of American Pathologists criteria, immunohistochemical (IHC) staining of 0 to &lt;1 percent should be considered negative, whereas ≥10 percent should be considered positive, and patients should not, or should, be candidates for ET, respectively. Tumors with ER 1 to 9 percent IHC staining are considered positive and ET should be considered, but may be less likely to be effective. (See
         <a class="medical medical_review" href="/z/d/html/747.html" rel="external">
          "Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy", section on 'Interpretation of ER and PR tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The approach to HER2 testing is summarized  (
         <a class="graphic graphic_table graphicRef118704" href="/z/d/graphic/118704.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131428" href="/z/d/graphic/131428.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IHC evaluation for programmed cell death ligand 1 (PD-L1) expression, among those with triple negative cancers
         </strong>
         , as this guides initial therapy selection. (See
         <a class="local">
          'Hormone receptor-negative, HER2-negative patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatic testing for genetic alterations
         </strong>
         – For those in whom hormone receptor positivity is confirmed, we assess tumor
         <em>
          PIK3CA
         </em>
         status, either at initial diagnosis of metastatic disease, or at the time of progression on first-line therapy. We assess this using the companion diagnostic test approved by the US Food and Drug Administration to select patients for possible second-line treatment with the alpha isoform-specific phosphoinositide 3-kinase inhibitor
         <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">
          alpelisib
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. The diagnostic test is approved for use on tumor tissue specimens and circulating tumor DNA for the detection of 11
         <em>
          PIK3CA
         </em>
         activating mutations. We prefer to use tissue, if it is available, given available trial data. However, if tumor tissue is not available, we assess plasma specimens for
         <em>
          PIK3CA
         </em>
         mutations. If the test is negative for
         <em>
          PIK3CA
         </em>
         mutations in plasma, more tissue should be acquired, when possible, for repeat testing for
         <em>
          PIK3CA
         </em>
         mutations in tumor tissue [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cell-free DNA "liquid biopsy" is a means of identifying targetable mutations, especially when tissue biopsy may be difficult [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Biopsy of a metastatic lesion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For all cancers irrespective of tumor receptor status, assessment for mutations in tropomyosin receptor kinase
         <em>
          (TRK
         </em>
         ) [
         <a href="#rid16">
          16,17
         </a>
         ], as well as for presence of microsatellite-high/DNA mismatch-repair deficiency and tumor mutational burden, should be performed. However, these assessments may be undertaken after progression on initial and subsequent-line therapy, as they guide later-line treatments [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy"
         </a>
         .)
        </p>
        <p>
         In 2015, the American Society of Clinical Oncology reported its guidelines about the role of rebiopsy, suggesting that it should be performed, but there is no prospective evidence that changing treatment based on the information of the metastatic biopsy affects outcomes. Neverthess, per this guideline, in case a biopsy is performed and discrepancy is found between the primary and metastatic tumors, information from the metastatic setting should be utilized for management decisions [
         <a href="#rid19">
          19
         </a>
         ]. A 2018 European Society for Medical Oncology (ESMO) guideline acknowledges the lack of prospective trials evaluating change in treatment based on IHC discrepancies between primary and metastatic tumors, but recommends consideration to utilize targeted treatment (endocrine therapy or anti-HER2 therapy) if the receptors are positive in at least one of the biopsies, regardless if in the primary or metastatic settings [
         <a href="#rid20">
          20
         </a>
         ]. Our strategy is consistent with the ESMO guideline, although we recognize that in the setting of limited data, other experts may adopt a different approach.
        </p>
        <p>
         The rates of discordance of receptor status between the primary and metastatic lesions vary, but typically range between 5 to 30 percent [
         <a href="#rid21">
          21,22
         </a>
         ]. This type of conversion may represent a biologic evolution, partly due to selection pressure from the different agents administered. Some experts believe that the conversion could also represent a methodologic phenomenon, linked to the type of HER2 testing that was conducted, the condition of the fixed paraffin-embedded block, and even a sampling issue, as tumors can be heterogeneous. One report evaluated the conversion rate of hormone receptors and HER2 and concluded that patient outcomes are dictated by the new phenotype and not by the characteristics of the primary tumor [
         <a href="#rid23">
          23
         </a>
         ]. However, this needs to be cautiously interpreted, in view of the influence of sampling or methodology errors, as we would not want to deprive patients from potentially effective targeted treatment [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2617013305">
         <span class="h2">
          Germline testing for BRCA1/2 pathogenic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline testing for breast cancer susceptibility gene 1 or 2 (
         <em>
          BRCA1
         </em>
         or
         <em>
          BRCA2
         </em>
         ) is also recommended for all patients with metastatic breast cancer in view of therapeutic options (poly[ADP-ribose] polymerase [PARP] inhibitors), as per National Comprehensive Cancer Network guidelines [
         <a href="#rid24">
          24-26
         </a>
         ]. (See
         <a class="local">
          'Special considerations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2550253719">
         <span class="h2">
          Laboratory and radiographic studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should have a complete blood count and comprehensive metabolic panel (including liver function tests) to determine whether the cancer is causing organ dysfunction, as well as whether any baseline comorbidities may affect the choice of treatment.
        </p>
        <p>
         Additionally, we perform computed tomography (CT) of the chest, abdomen, and pelvis and nuclear medicine bone scan to determine the extent of disease. Positron emission tomography/CT may be obtained, alternatively.
        </p>
        <p>
         Further imaging may be appropriate to evaluate specific signs or symptoms, as well. For example, for those with signs or symptoms suggestive of central nervous system involvement, we obtain dedicated imaging such as contrast-enhanced magnetic resonance imaging of the brain and/or spinal cord.
        </p>
        <p class="headingAnchor" id="H133804">
         <span class="h2">
          Prediction of response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are predictors of treatment response:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hormone receptor status and HER2 overexpression are the most important predictors of treatment response in patients with MBC. (See
         <a class="medical medical_review" href="/z/d/html/88415.html" rel="external">
          "Prognostic and predictive factors in metastatic breast cancer", section on 'Tests done on metastatic tissue'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of specific genetic alterations predicts response to certain targeted agents (eg, PARP inhibitors in germline
         <em>
          BRCA1/2
         </em>
         mutation
         <em>
         </em>
         carriers, or tumor
         <em>
          TRK
         </em>
         fusions for
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         or
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In regards to response to chemotherapy, consistent predictors of poor response are progression with prior chemotherapy for advanced disease, relapse within 12 months of completing adjuvant chemotherapy, poor performance status, and multiple metastatic disease sites [
         <a href="#rid27">
          27-37
         </a>
         ]. Patients with visceral metastases (especially if rapidly progressing) generally have an aggressive phenotype, while patients with soft tissue and bone metastases, or bone metastases only, have a more indolent phenotype.
        </p>
        <p>
        </p>
        <p>
         The detection and monitoring of circulating tumor cells during treatment for MBC is discussed below. (See
         <a class="local">
          'Circulating tumor cells'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1904101873">
         <span class="h1">
          HER2-NEGATIVE TUMORS
         </span>
        </p>
        <p class="headingAnchor" id="H361864767">
         <span class="h2">
          Hormone receptor-positive, HER2-negative disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, endocrine therapy (with cyclin-dependent kinase [CDK] 4/6 inhibition) is beneficial for these patients, with fewer side effects compared with chemotherapy. Therefore, these options should be used as initial treatment for most patients with hormone receptor-positive disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selection of endocrine therapy and accompanying targeted agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selection of chemotherapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special considerations for patients with germline breast cancer susceptibility gene 1/2 (
         <em>
          BRCA1/2
         </em>
         ) mutations are discussed below. (See
         <a class="local">
          'Special considerations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H85043981">
         <span class="h3">
          Choosing between endocrine therapy and chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to endocrine versus chemotherapy in hormone receptor-positive, HER2-negative metastatic cancers is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since ET (alone or in combination with targeted agents) is generally less toxic than chemotherapy, with comparable outcomes [
         <a href="#rid38">
          38,39
         </a>
         ], it is preferable for most patients with hormone receptor-positive disease to begin treatment with ET. (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the minority of patients who have extensive visceral metastases, chemotherapy may be considered an appropriate alternative to endocrine therapy plus targeted agents; however, there are no data suggesting a survival benefit to this approach. (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who progress after two lines of ET (with or without a targeted agent), or in whom rapid progression on ET has been observed, chemotherapy may be appropriate, depending on patient comorbidities and individual preferences. (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H361864774">
         <span class="h2">
          Hormone receptor-negative, HER2-negative patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with triple-negative (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, human epidermal growth factor receptor 2 [HER2]-negative) breast cancer have a particularly aggressive subtype, and first-line chemotherapy is recommended, with or without immunotherapy. Triple-negative breast cancer is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer"
         </a>
         .)
        </p>
        <p>
         Briefly,
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial treatment for metastatic triple-negative breast cancer is guided by expression of tumor programmed cell death ligand 1 (PD-L1), an immune checkpoint. Immune checkpoint inhibitor plus chemotherapy is offered in the first-line treatment for patients with for PD-L1-positive disease. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'PD-L1 combined positive score of at least 10'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most other patients are treated with chemotherapy alone, although some germline
         <em>
          BRCA1/2
         </em>
         mutation carriers are treated with poly(ADP-ribose) polymerase (PARP) inhibitors. (See
         <a class="local">
          'Special considerations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether chemotherapy agents are given in combination or sequentially should be determined based on symptoms and location and burden of disease, as well as patient-related factors (ie, preferences, goals, and overall health). (See
         <a class="local">
          'Sequential single agents versus combination chemotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As a later-line option,
         <a class="drug drug_general" data-topicid="127999" href="/z/d/drug information/127999.html" rel="external">
          sacituzumab govitecan
         </a>
         (SG) is an antibody-drug conjugate targeting trophoblast cell-surface antigen-2 (TROP-2), which is upregulated in breast cancer [
         <a href="#rid40">
          40,41
         </a>
         ]. SG is comprised of sacituzumab conjugated via a pH-labile hydrolyzable linker to SN-38 (the active metabolite of
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         ). SG is US Food and Drug Administration (FDA) approved for patients with unresectable/locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Sacituzumab govitecan'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3853132013">
         <span class="h2">
          Special considerations
         </span>
        </p>
        <p class="headingAnchor" id="H1362933786">
         <span class="h3">
          BRCA 1/2 and PALB2 associated tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline mutations in breast cancer susceptibility genes 1 and 2 (
         <em>
          BRCA1
         </em>
         and
         <em>
          BRCA2
         </em>
         ) have been detected in 5 percent of patients with metastatic breast cancer [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with HER2-negative breast cancer with
         <strong>
          germline
         </strong>
         <strong>
          <em>
           BRCA1/2
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting (and who have also received at least one line of endocrine therapy, if they have hormone receptor-positive disease), we suggest an oral inhibitor of poly(ADP-ribose) polymerase (PARP) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additionally, for patients with metastatic HER2-negative breast cancer who have either pathogenic
         <strong>
          somatic
         </strong>
         <strong>
          <em>
           BRCA1/2
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         or germline partner and localizer of
         <em>
          BRCA2
         </em>
         <strong>
          (
         </strong>
         <strong>
          <em>
           PALB2
          </em>
         </strong>
         <strong>
          )
         </strong>
         <strong>
          mutations
         </strong>
         , and have received prior chemotherapy (and endocrine therapy, if appropriate), we also suggest PARP inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PARP inhibitors (
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         or
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          talazoparib
         </a>
         ) should be used sequentially after or before chemotherapy rather than concurrently. Concurrent use of PARP inhibitors with CDK/4/6 inhibitors has not been tested in clinical trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The approach and supporting data for PARP inhibitors among patients specifically with germline
         <em>
          BRCA1/2
         </em>
         mutation-associated, triple-negative breast cancer are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Germline BRCA mutation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Two trials have demonstrated the single-agent activity of the oral inhibitors of PARP
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         and
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          talazoparib
         </a>
         in this setting. In these trials, patients with germline
         <em>
          BRCA1/2
         </em>
         mutations and metastatic disease, who had previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, were randomly assigned to the PARP inhibitor or to one of a few single-agent chemotherapeutic agents, which were chosen at the discretion of the treating clinician. In both trials, the PARP inhibitor was superior to chemotherapy for progression-free survival (PFS), the primary endpoint, as well as for response and toxicity. Thus, PARP inhibitors in this setting proved more effective and less toxic than conventional chemotherapy. However, neither of these trials compared PARP inhibitors specifically against platinum-based chemotherapy, though each study showed measurable clinical activity of the PARP inhibitor among the subset of patients previously treated with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         .
        </p>
        <p>
         Further supporting the use of PARP inhibitors for germline
         <em>
          BRCA1/2
         </em>
         mutation-associated cancers, in preliminary reporting of a separate trial, the addition of the PARP inhibitor veliparib to
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         among patients with ≤2 prior lines of cytotoxic therapy for metastatic,
         <em>
          BRCA1/2
         </em>
         mutation-associated breast cancer improved median PFS (14.5 versus 12.6 months; hazard ratio [HR] 0.71, 95% CI 0.57-0.88) [
         <a href="#rid44">
          44
         </a>
         ]. OS results were similar (33.5 versus 28.2 months; HR 0.95, 95% CI 0.73-1.2) between the two groups. Veliparib does not have regulatory approval in metastatic breast cancer.
        </p>
        <p class="headingAnchor" id="H4175128860">
         <span class="h4">
          Talazoparib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          Talazoparib
         </a>
         is FDA approved for patients with germline
         <em>
          BRCA1/2
         </em>
         mutations and HER2-negative, locally advanced or metastatic breast cancer [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         In the phase III EMBRACA trial, 431 patients with metastatic, HER2-negative, germline
         <em>
          BRCA1/2
         </em>
         mutation-associated breast cancer were randomly assigned in a 2:1 ratio to
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          talazoparib
         </a>
         or to chemotherapy (either single-agent
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At a median follow-up of approximately 11 months, those receiving
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          talazoparib
         </a>
         experienced an improved PFS relative to those treated with chemotherapy (median 8.6 versus 5.6 months, respectively; HR 0.54, 95% CI 0.41-0.71). With more than three years' follow-up, differences in OS between the two groups were not significantly different [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">
          Talazoparib
         </a>
         caused more anemia than standard chemotherapy; rates of neutropenia were comparable. For most nonhematologic toxicities, talazoparib was better tolerated. Patients receiving talazoparib reported significant improvements in quality of life, while those receiving chemotherapy reported worsened quality of life outcomes [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2417581695">
         <span class="h4">
          Olaparib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          Olaparib
         </a>
         is FDA approved for germline
         <em>
          BRCA1/2
         </em>
         mutation carriers with metastatic, HER2-negative breast cancer previously treated with chemotherapy (and endocrine therapy, if appropriate). We also suggest it for those with pathogenic somatic
         <em>
          BRCA1/2
         </em>
         mutations and in patients with germline
         <em>
          PALB2
         </em>
         mutation, previously treated with chemotherapy.
        </p>
        <p>
         In the phase III OlympiAD trial, over 300 patients with metastatic, HER2-negative, germline
         <em>
          BRCA1/2
         </em>
         mutation-associated breast cancer were randomly assigned in a 2:1 ratio to
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         or to chemotherapy (either single-agent
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16096" href="/z/d/drug information/16096.html" rel="external">
          eribulin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. All patients had received an anthracycline and a taxane in either the adjuvant or metastatic setting, and those with hormone receptor-positive disease had also received prior endocrine therapy.
        </p>
        <p>
         At a median follow-up of approximately 14 months, those receiving
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         experienced an improved PFS relative to those treated with chemotherapy (7.0 versus 4.2 months, respectively; HR 0.58, 95% CI 0.43-0.80). OS between the two groups at approximately 25 months of follow-up was not significantly different, except for the prespecified subgroup with no prior chemotherapy for MBC (HR 0.51, 95% CI 0.29-0.90) [
         <a href="#rid48">
          48,49
         </a>
         ]. PFS improvements with olaparib were greater in the triple-negative subgroup (HR 0.43, 95% CI 0.29-0.63) than among patients with hormone receptor-positive disease (HR 0.82, 95% CI 0.55-1.26).
        </p>
        <p>
         The rate of grade 3 or higher adverse events was lower with
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         than with chemotherapy (38 versus 50 percent), with anemia, nausea, vomiting, fatigue, headache, and cough occurring more frequently with olaparib, and neutropenia, palmar-plantar erythrodysesthesia, and liver function test abnormalities occurring more commonly with chemotherapy.
        </p>
        <p>
         An open-label, single-arm phase IIIb study found similar efficacy (median PFS with
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         of about eight months) and safety outcomes among similar patients as OlympiAD, in a setting reflecting clinical practice [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         In a single-arm phase II study,
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         has also shown activity among those with pathogenic somatic
         <em>
          BRCA1/2
         </em>
         mutations and germline
         <em>
          PALB2
         </em>
         mutations, although PARP inhibitor therapy has not been evaluated in randomized trials in these populations [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1997152297">
         <span class="h3">
          HER2-low tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          Fam-trastuzumab deruxtecan
         </a>
         is approved by the FDA for patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy [
         <a href="#rid52">
          52
         </a>
         ]. We use this option in hormone receptor-positive disease only if refractory to endocrine therapy.
        </p>
        <p>
         In a randomized trial, 557 patients with metastatic breast cancer who had received one or two previous lines of chemotherapy were enrolled, all of whom had cancers that were 1+ for HER2 on IHC, or 2+ on IHC with negative FISH [
         <a href="#rid53">
          53
         </a>
         ]. In this trial, the antibody-drug conjugate
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          fam-trastuzumab deruxtecan
         </a>
         resulted in longer progression-free and overall survival compared to treatment with physician’s choice of chemotherapy (TPC). The median PFS was 9.9 months versus 5.1 months respectively, among those receiving fam-trastuzumab deruxtecan and TPC (HR 0.50, 95% CI, 0.40-0.63); median OS was 23.4 months versus 16.8 months, respectively (HR 0.64, 95% CI, 0.49-0.84). Approximately 11 percent of patients enrolled in this study had hormone receptor negative disease; benefit of fam-trastuzumab deruxtecan over TPC was noted in both hormone receptor-positive and hormone receptor-negative subgroups.
        </p>
        <p>
         Adverse events of ≥grade 3 occurred in 53 percent of the patients who received
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         deruxtecan and 67 percent of those who received TPC. Drug-related interstitial lung disease or pneumonitis occurred in 12 percent receiving
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          fam-trastuzumab deruxtecan
         </a>
         , 0.8 percent had grade 5 events.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          Fam-trastuzumab deruxtecan
         </a>
         has been endorsed by expert guidelines from the American Society of Clinical Oncology [
         <a href="#rid54">
          54
         </a>
         ]. This agent also has an established role in HER2-positive metastatic breast cancer. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2790003249">
         <span class="h1">
          HER2-POSITIVE CANCERS
         </span>
        </p>
        <p class="headingAnchor" id="H892937615">
         <span class="h2">
          Hormone receptor-positive, HER2-positive patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic options for these patients include chemotherapy, endocrine therapy, and human epidermal growth factor receptor 2 (HER2)-directed therapy. HER2-directed therapy has demonstrated improved survival for patients with tumors that overexpress HER2 and thus should be part of first-line therapy for these patients.
        </p>
        <p>
         Whether it is better to use HER2-directed therapy combined with chemotherapy versus endocrine therapy as first-line treatment is unclear. HER2-directed therapy combined with chemotherapy or endocrine therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H361864781">
         <span class="h2">
          Hormone receptor-negative, HER2-positive patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of human epidermal growth factor receptor 2 (HER2)-directed therapy and chemotherapy is recommended for treatment-naϊve patients. Regimens combining HER2-directed therapy with chemotherapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3596114512">
         <span class="h1">
          LATER-LINE OPTIONS, IRRESPECTIVE OF TUMOR RECEPTOR STATUS
         </span>
        </p>
        <p class="headingAnchor" id="H3586477175">
         <span class="h2">
          For TRK fusion-positive cancers
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with tropomyosin receptor kinase (
         <em>
          TRK
         </em>
         )
         <em>
          -
         </em>
         positive cancers that have progressed on other available options, we offer treatment with TRK inhibitors (ie,
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         ) [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H300579926">
         <span class="h2">
          For cancers with high TMB or MSI-H
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with microsatellite-high (MSI-H)/DNA mismatch-repair deficient unresectable or metastatic breast cancer (regardless of estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2] status) may also benefit from
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         or dostarlimab-gxly after progression on other treatment options. Similarly, patients with high tumor mutational burden (TMB; ≥10 mutations/megabase) unresectable or metastatic breast cancer (regardless of ER, PR, and HER2 status) may also benefit from pembrolizumab, after progression on other treatment options [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         .)
        </p>
        <p>
         Supporting data largely come from "basket" studies, evaluating
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in tumors representing multiple different primary sites that have these molecular features. However, these trials typically included only small numbers of patients with breast cancer [
         <a href="#rid55">
          55
         </a>
         ]. Data from such studies and the approach to patients with breast cancer are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Clinical efficacy of anti-PD-1 therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2676672458">
         <span class="h1">
          ADDITIONAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3891506939">
         <span class="h2">
          Sequential single agents versus combination chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, single-agent chemotherapy, used in sequence, is preferable to combination chemotherapy, since the single-agent chemotherapy is reasonably likely to induce palliation with fewer side effects, and no studies have demonstrated an overall survival (OS) benefit for the combination chemotherapy as long as both drugs are available in sequence. Combination chemotherapy (rather than single-agent, sequential therapy) is most appropriate when the higher chance of response is assessed to be more important than the potential for higher treatment toxicity, due to concerns about impending organ dysfunction from existing or rapidly progressing disease burden. However, both clinicians and patients should know there are no prospective data that show that combination chemotherapy improves OS compared with single-agent, sequential cytotoxic chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Combination versus single agent chemotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1539546902">
         <span class="h2">
          Combining different forms of systemic treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In theory, combining chemotherapy, biologic therapy, and/or endocrine therapy might have additive efficacy, but it might also lead to increased toxicity. Clinical trials have failed to show a survival advantage for the concurrent administration of chemotherapy and endocrine therapy over either single modality [
         <a href="#rid7">
          7,56,57
         </a>
         ].
        </p>
        <p>
         However, human epidermal growth factor receptor 2 (HER2)-directed therapy (
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         , etc) has been successfully combined as individual agents with chemotherapy and endocrine therapy, and with each other. Likewise, endocrine therapies have been successfully combined with targeted treatments like cyclin-dependent kinase 4/6 inhibitors, mechanistic target of rapamycin inhibitors, and phosphoinositide-3 kinase inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4262387873">
         <span class="h2">
          Local treatments for the primary or metastatic sites
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although systemic therapy is the mainstay of treatment for metastatic breast cancer, local management of both of the primary breast cancer, as well as metastasis-specific local treatment (ie, metastasectomy, radiation therapy, surgery, etc.) may palliate symptoms and prevent cancer-related complications. Some evidence suggests a potential for prolonging survival, although available data are limited and conflicting. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/760.html" rel="external">
          "The role of local therapies in metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3497437456">
         <span class="h2">
          Osteoclast inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with bone metastases should be treated with osteoclast inhibitors (bisphosphonates or receptor activator of nuclear kappa-B [RANK] ligand inhibition), as these agents have been shown to reduce the risk of skeletal-related events such as fractures, the need for surgery or radiation to bone, spinal cord compression, and hypercalcemia of malignancy. (See
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/776.html" rel="external">
          "Use of osteoclast inhibitors in early breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          MONITORING THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful assessment of the response to therapy will assist in decisions for duration of treatment and in selection of subsequent treatments. However, the best approach for monitoring patients with MBC is not well established. Overall survival (OS) is the gold standard for comparing therapies, but it requires prolonged follow-up and may be diluted by the effects of subsequent treatment. However, no other endpoint, including progression-free survival (PFS), time to tumor progression, or objective response rate, has been shown to be a good surrogate for OS [
         <a href="#rid58">
          58
         </a>
         ]. Comparisons of objective response rates are often used to determine relative treatment efficacy, but high response rates do not necessarily translate into clinically meaningful increases in survival [
         <a href="#rid58">
          58-60
         </a>
         ]. In addition, symptom relief without measurable disease response and achievement of stable disease as compared with disease progression may be clinically important [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          History and examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         If symptom palliation is the main objective, clinical history alone may suffice to determine the success of therapy. Physical examination may allow response quantitation if disease is easily accessible (eg, chest wall nodules, palpable lymphadenopathy). With a dramatic reduction in symptoms that were clearly disease related or obvious shrinkage of palpable lesions, serum markers and radiographic tests are likely to be irrelevant.
        </p>
        <p>
         However, many patients have more subtle disease signs or symptoms that may be confused with treatment toxicity or other nonmalignant conditions. In addition, disease is not measurable by physical examination in nearly one-half of patients with MBC. In these patients, serial changes in tumor markers or radiographic studies are essential in establishing the response to therapy.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Tumor markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serial assay of serum tumor markers (eg, cancer antigen [CA] 15-3 and CA 27.29, both products of the mucin 1 [
         <em>
          MUC1
         </em>
         ] gene, and carcinoembryonic antigen [CEA]) can aid in response assessment, particularly if disease sites are not assessable by usual criteria [
         <a href="#rid62">
          62,63
         </a>
         ]. Judicious use of serial tumor marker measurements may decrease the need for periodic radiographic evaluation [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Guidelines from the American Society of Clinical Oncology (ASCO) expert panel suggest that it is reasonable to evaluate CA 15-3, CA 27.29, and CEA initially in patients with metastatic disease [
         <a href="#rid62">
          62
         </a>
         ]. If CA 15-3 and/or CA 27.29 are elevated, there is no role for monitoring CEA, but if not, serial measurement of CEA levels may be useful.
        </p>
        <p>
         Elevated tumor markers may occasionally be spurious. Thus, for patients without clear clinical or radiographic signs of progression, a rise in tumor markers alone should not dictate a change in treatment, although more frequent monitoring may be appropriate, in some instances. Up to 20 percent of patients successfully treated with systemic therapy may experience a transient increase (marker "flare") during the first one or two months after treatment initiation, presumably due to release of antigen by cytolysis [
         <a href="#rid65">
          65,66
         </a>
         ]. Patients with abnormal liver function may also have falsely elevated marker levels because they are cleared by the liver [
         <a href="#rid65">
          65
         </a>
         ]. CA 15-3 levels may be aberrantly elevated in patients with vitamin B12 deficiency and megaloblastic anemia, as well as in patients with thalassemia or sickle cell disease [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Radiographic studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serial plain radiographs, computed tomography (CT) scan, or magnetic resonance imaging (MRI) can permit assessment of tumor response. A reasonable frequency of routine monitoring is every two to four months, although scans may be obtained earlier if there are clinical signs or symptoms of progression. Periodic scintigraphic bone scans, while helpful, may also be misleading. Technetium (Tc99) phosphonate accumulates in areas of osteoblastic activity rather than in cancer cells. In a patient experiencing a response to therapy, a "scintigraphic healing flare" may appear as early as two months and persist for as long as 12 months after initiating therapy [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p>
         Integrated positron emission tomography (PET)/CT is popular as a whole-body examination in monitoring response to therapy in MBC, as it has demonstrated high sensitivity and specificity in detecting metastatic disease and can reliably assess response to therapy [
         <a href="#rid72">
          72-74
         </a>
         ]. There is also some evidence that metabolic changes in bone metastases in response to systemic therapy (ie, a change in standardized uptake value) can predict response duration or time to progression [
         <a href="#rid75">
          75-77
         </a>
         ]. However, many integrated PET/CT scanners in clinical use provide a limited CT scan primarily for orientational purposes (determining where the PET abnormality is) and not a higher-resolution, fine-cut, contrast-enhanced CT scan. This should be kept in mind when evaluating response between modalities (standard CT and PET/CT). There are no studies to demonstrate whether it is preferable to monitor patients with either PET/CT or scintigraphic bone scanning and dedicated CT or MRI.
        </p>
        <p class="headingAnchor" id="H2088574728">
         <span class="h2">
          Approach not routinely used
         </span>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h3">
          Circulating tumor cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of circulating tumor cells (CTCs) in blood samples of patients with MBC (≥5 CTCs per 7.5 mL of blood) has been shown to be a predictor of PFS and OS [
         <a href="#rid78">
          78-84
         </a>
         ]. However, the role of CTCs in the monitoring of patients remains controversial. Therefore, we agree with ASCO expert panels, which have concluded that measurement of CTCs should not be used to influence treatment decisions in metastatic disease at this time [
         <a href="#rid62">
          62,85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88415.html" rel="external">
          "Prognostic and predictive factors in metastatic breast cancer", section on 'Circulating tumor cells'
         </a>
         .)
        </p>
        <p>
         Immunologic and RNA-based methods are used to detect CTCs in breast cancer. In a prospective trial of 177 patients who were beginning a new therapy for MBC [
         <a href="#rid79">
          79
         </a>
         ], elevated CTCs at baseline (defined as five or more CTCs per 7.5 mL of blood) compared with the finding of fewer or no detectable CTCs predicted a significantly shorter PFS (median, three versus seven months) and OS (median, 10 versus 22 months). Patients with elevated CTCs at the first follow-up visit (within three to five weeks of initiating therapy) also had a worse PFS (median, two versus seven months) and OS (median, 8 versus greater than 18 months), whereas those with a decrease in the number of CTCs from baseline had improved PFS and OS. Subsequent analyses from this trial and others have suggested that elevated levels of CTCs at any time point during treatment are associated with tumor progression and that CTC levels may reliably estimate disease progression earlier than imaging studies [
         <a href="#rid81">
          81,84,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H453568818">
         <span class="h1">
          DURATION OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unlike in the adjuvant setting, there is no predetermined duration of treatment. Therefore, the duration of therapy should be individualized, taking into account the patient's goals of treatment, disease response, presence of side effects, and alternative options that might be available. In general, patients should continue treatment to the best response, disease progression, or when toxicity requires discontinuation of treatment.
        </p>
        <p>
         For patients on combination chemotherapy, discussion of the use of chemotherapy beyond best response (ie, maintenance therapy) is covered separately. (See
         <a class="medical medical_review" href="/z/d/html/83848.html" rel="external">
          "Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Duration of treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H105835326">
         <span class="h1">
          DEFINITION OF TREATMENT FAILURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our own practice, we monitor for treatment failure by taking into account serial changes in symptoms, physical findings, or tumor markers, as well as evidence of disease progression based on serial imaging. Some criteria that we use to define treatment failure include any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical deterioration during treatment (ie, increasing disease-related symptoms, intolerable treatment toxicities, declining performance status)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of new metastases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing size of previously documented metastatic lesions
        </p>
        <p>
        </p>
        <p>
         The primary role of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is to standardize the reporting of results on clinical trials  (
         <a class="graphic graphic_table graphicRef57181" href="/z/d/graphic/57181.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid87">
          87
         </a>
         ]. RECIST primarily applies to imaging of metastatic disease, and it encompasses two of the three reasons for treatment failure.
        </p>
        <p>
         According to RECIST, disease progression on imaging is defined as any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 20 percent or more increase in the sum of measurable target lesions compared with the smallest sum previously recorded
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The appearance of any new lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Worsening of existing nontarget lesions, for example, bone metastases
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2471707082">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical factors that predict the rate of progression and survival include the interval between initial diagnosis and relapse, the number of metastatic sites, the presence or absence of visceral involvement, performance status, and biologic markers. The role of these factors is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/88415.html" rel="external">
          "Prognostic and predictive factors in metastatic breast cancer", section on 'Prognostic factors'
         </a>
         .)
        </p>
        <p>
         Median survival for patients with MBC appears to have improved over time, a trend which has been attributed to the availability of new, more effective agents, including taxanes, aromatase inhibitors, cyclin-dependent kinase 4/6 inhibitors, and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          pertuzumab
         </a>
         , and other human epidermal growth factor receptor 2 (HER2) targeted agents [
         <a href="#rid1">
          1,2,88-90
         </a>
         ]. As an example, a meta-analysis and systematic review of 15 studies of recurrent MBC (n = 18,678 patients) revealed no survival improvement among patients recurring between 1980 and 1990, but median survival increased from 21 to 38 months from 1990 to 2010 [
         <a href="#rid4">
          4
         </a>
         ]. Based on this study, patients with estrogen receptor (ER)-positive MBC now have a median overall survival of 57 months, and patients with ER-negative MBC have a median survival of 33 months.
        </p>
        <p class="headingAnchor" id="H288552351">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119888.html" rel="external">
          "Society guideline links: Hereditary breast and ovarian cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">
          "Society guideline links: Breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/865.html" rel="external">
          "Patient education: Treatment of metastatic breast cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H459263114">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of treatment
         </strong>
         – The goals of systemic treatment for metastatic breast cancer (MBC) are prolongation of survival, alleviation of symptoms, and maintenance or improvement in quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of metastatic tumor biology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Given the importance of hormone receptor and human epidermal growth factor receptor 2 (HER2) status in selecting treatment, hormone receptor and HER2 testing should be repeated upon diagnosis of MBC. (See
         <a class="local">
          'Tumor assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of germline breast cancer susceptibility gene 1 or 2 (
         <em>
          BRCA1
         </em>
         or
         <em>
          BRCA2
         </em>
         ) mutations, tumor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (
         <em>
          PIK3CA
         </em>
         )
         <em>
         </em>
         mutation status, and tumor programmed cell death ligand 1 (PD-L1) status should also be assessed in a metastatic lesion, as they are important determinants in selecting appropriate treatment. (See
         <a class="local">
          'Tumor assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HER2-negative disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hormone receptor-positive, HER2-negative disease
         </strong>
         – For most patients with hormone receptor-positive, HER2-negative MBC, we recommend initial treatment with endocrine therapy plus targeted therapy, rather than chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). This includes patients with rapidly progressive, symptomatic disease or visceral metastases, although chemotherapy may be an acceptable alternative. Chemotherapy is used for endocrine-refractory disease. (See
         <a class="local">
          'Hormone receptor-positive, HER2-negative disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Triple-negative disease
         </strong>
         – Many patients with triple-negative (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, HER2-negative) breast cancer have a particularly aggressive subtype, and first-line chemotherapy is recommended, with or without immunotherapy. Immune checkpoint inhibitor plus chemotherapy is offered in the first-line treatment for patients with for PD-L1-positive disease. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'PD-L1 combined positive score of at least 10'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selection of chemotherapy is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">
          "ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Initial treatment in the absence of rapidly progressive visceral disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BRCA1/2
          </em>
         </strong>
         <strong>
          and
         </strong>
         <strong>
          <em>
           PALB2
          </em>
         </strong>
         <strong>
          associated tumors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with metastatic, HER2-negative breast cancer with
         <strong>
          germline
         </strong>
         <strong>
          <em>
           BRCA1/2
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting (and who have also received at least one line of endocrine therapy, if they have hormone receptor-positive disease), we suggest an oral inhibitor of poly(ADP-ribose) polymerase (PARP) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those with metastatic, HER2-negative breast cancer with either germline
         <strong>
          partner and localizer of
         </strong>
         <strong>
          <em>
           BRCA2
          </em>
         </strong>
         <strong>
          (
         </strong>
         <strong>
          <em>
           PALB2
          </em>
         </strong>
         <strong>
          ) mutations
         </strong>
         or
         <strong>
          somatic
         </strong>
         <strong>
          <em>
           BRCA1/2
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         , we also suggest treatment with a PARP inhibitor (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), after progression on chemotherapy (and endocrine therapy, if appropriate). (See
         <a class="local">
          'Special considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HER2-low cancers
         </strong>
         – For patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-negative) breast cancer who have received ≥1 prior chemotherapy in the metastatic setting, or developed disease recurrence during or within six months of completing adjuvant chemotherapy, we recommend
         <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">
          fam-trastuzumab deruxtecan
         </a>
         rather than further lines of chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We use this option in hormone receptor-positive disease only if refractory to endocrine therapy. (See
         <a class="local">
          'HER2-low tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HER2-positive disease
         </strong>
         – For patients with HER2-positive breast cancer, regardless of the hormone receptor status, we incorporate HER2-directed therapy in their first-line treatment. HER2-directed therapy combined with chemotherapy or endocrine therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15749.html" rel="external">
          "Systemic treatment for HER2-positive metastatic breast cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring therapy
         </strong>
         – Careful assessment of the response to therapy will assist in decisions for treatment continuation and in selection of subsequent treatments. Tools that are potentially useful to monitor treatment response include history and physical examination, radiographic imaging, and/or assay of serum tumor markers. The role of circulating tumor cells continues to be actively investigated. (See
         <a class="local">
          'Monitoring therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Median survival for patients with MBC appears to have improved over time, a trend which has been attributed to the availability of new, more effective agents, including taxanes, aromatase inhibitors, and
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         . (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr 2018; 2:pky062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osoba D. Health-related quality of life as a treatment endpoint in metastatic breast cancer. Can J Oncol 1995; 5 Suppl 1:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29:456.
          </a>
         </li>
         <li class="breakAll">
          United States Food and Drug Administration press release. FDA approves alpelisib for metastatic breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer (Accessed on May 30, 2019).
         </li>
         <li class="breakAll">
          Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update (Accessed on July 20, 2022).
         </li>
         <li class="breakAll">
          Alpelisib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf (Accessed on May 30, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cisneros-Villanueva M, Hidalgo-Pérez L, Rios-Romero M, et al. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer 2022; 126:391.
          </a>
         </li>
         <li class="breakAll">
          Entrectinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf (Accessed on September 03, 2019).
         </li>
         <li class="breakAll">
          Larotrectinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf (Accessed on September 03, 2019).
         </li>
         <li class="breakAll">
          Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s055s056lbl.pdf (Accessed on September 03, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Poznak C, Somerfield MR, Bast RC, et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2015; 33:2695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014; 50:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379:753.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2019. http://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Accessed on July 08, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmann DL, Schaid DJ, Ingle JN, et al. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol 1991; 14:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998; 16:2401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986; 58:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur. Am J Clin Oncol 1990; 13:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falkson G, Gelman R, Falkson CI, et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinovich M, Vallejo C, Bianco A, et al. Development and validation of prognostic models in metastatic breast cancer: a GOCS study. Oncology 1992; 49:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pronzato P, Bertelli G, Gardin G, et al. Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. Oncology 1993; 50:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995; 13:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15:3171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 2021; 32:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahan Z, Gil-Gil M, Ruiz-Borrego M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Eur J Cancer 2021; 156:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival. PLoS One 2014; 9:e96993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018; 9:28989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fasching PA, Yadav S, Hu C, et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39:1619.
          </a>
         </li>
         <li class="breakAll">
          Olaparib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf?et_cid=39929762&amp;et_rid=931310737&amp;linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f208558s001lbl.pdf (Accessed on September 30, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieras VC, Han HS, Kaufman B, et al. Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Ann Oncol 2019; 30S: ESMO #LBA9.
          </a>
         </li>
         <li class="breakAll">
          Talazoparib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf (Accessed on September 30, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020; 31:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 2018; 29:1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 2023; 184:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelmon KA, Fasching PA, Couch FJ, et al. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer 2021; 152:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 2020; 38:4274.
          </a>
         </li>
         <li class="breakAll">
          ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for
intravenous use. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s022lbl.pdf (Accessed on August 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moy B, Rumble RB, Carey LA, Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative Expert Panel. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2022; 40:3088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol 2021; 39:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 1986; 4:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmann DL, Schaid DJ, Bisel HF, et al. The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 1987; 5:1928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23:5117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson JF, Howell A, Buzdar A, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 1999; 58:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung KL, Evans AJ, Robertson JF. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 2001; 67:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson JF, Whynes DK, Dixon A, Blamey RW. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 1995; 72:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symeonidis A, Kouraklis-Symeonidis A, Apostolopoulos D, et al. Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology 2004; 67:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symeonidis A, Kouraklis-Symeonidis A, Constantinidou I, et al. Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia. Br J Haematol 2006; 133:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boga C, Ozdogu H, Sezgin N, et al. Serum cancer antigen 15-3 concentrations in patients with sickle cell disease. Br J Haematol 2006; 134:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology 1994; 192:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel CL, Schoenfelder J, Shemano I, et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011; 22:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007; 27 Suppl 1:S215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002; 9:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008; 247:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007; 105:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weigelt B, Bosma AJ, Hart AA, et al. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003; 88:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong NS, Kahn HJ, Zhang L, et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008; 113:2422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12:6403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27:5153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004; 100:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri D, Polyzos NP, Salanti G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008; 100:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28:92.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 767 Version 68.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17647245" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16149088" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19915976" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Fifteen-year trends in metastatic breast cancer survival in Greece.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30627694" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20220104" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19608616" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Third consensus on medical treatment of metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10814559" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8853525" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Health-related quality of life as a treatment endpoint in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10856099" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8708708" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189397" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189397" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189397" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21189397" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35027672" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cell-free DNA analysis in current cancer clinical trials: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35027672" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cell-free DNA analysis in current cancer clinical trials: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35027672" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cell-free DNA analysis in current cancer clinical trials: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35027672" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cell-free DNA analysis in current cancer clinical trials: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26195705" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30032243" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21041379" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24269135" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22711854" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28578601" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30110579" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30110579" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/427797" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6668494" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Multivariate analysis of prognostic factors in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2031502" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9667257" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Construction and validation of a practical prognostic index for patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3755647" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2198793" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1960558" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1495745" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Development and validation of prognostic models in metastatic breast cancer: a GOCS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8233288" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7751891" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9336352" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33385521" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34425406" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24824621" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Trop-2 is a determinant of breast cancer survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29989029" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33780288" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33780288" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32828825" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30124753" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30689707" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36893711" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34087573" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33119476" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33119476" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35665782" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35926153" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33844595" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779724" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2868074" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18421050" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3316516" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15955906" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10674881" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17954709" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11561773" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7599049" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10066086" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2295042" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Tumor marker kinetics in the monitoring of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15713991" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16704450" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Increased CA-15.3 levels in the serum of patients with homozygous beta-thalassaemia and sickle cell/beta-thalassaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16856886" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Serum cancer antigen 15-3 concentrations in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8208938" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Healing flare in skeletal metastases from breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537797" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19801220" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Breast cancer: role of SPECT and PET in imaging bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624786" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18180228" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : FDG PET, PET/CT, and breast cancer imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12186440" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18372468" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17268819" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12671691" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15317891" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15735118" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16857794" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16541316" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18785255" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17085652" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29504847" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19752342" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14692023" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Is breast cancer survival improving?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19066278" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933921" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
